These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Clinical application of pre-programmed insulin infusion: continuous subcutaneous insulin therapy with a portable infusion system. Pickup JC; Viberti GC; Keen H; Parsons JA; Alberti KG Horm Metab Res Suppl; 1979; (8):202-4. PubMed ID: 395081 [TBL] [Abstract][Full Text] [Related]
8. [Blood sugar control in diabetics with the insulin pump. Comparison with discontinuous injections]. Sudre Y; Abadie JC; Marechaud R; Rossi F; Gouet D; Queron B Sem Hop; 1982 Sep; 58(32):1801-4. PubMed ID: 6291163 [TBL] [Abstract][Full Text] [Related]
9. Continuous subcutaneous insulin infusion:good blood glucose control for up to 4 days. Pickup JC; Keen H; Parsons JA; Alberti KG Diabetologia; 1979 Jun; 16(6):385-9. PubMed ID: 467848 [TBL] [Abstract][Full Text] [Related]
10. Management of severely brittle diabetes by continuous subcutaneous and intramuscular insulin infusions: evidence for a defect in subcutaneous insulin absorption. Pickup JC; Home PD; Bilous RW; Keen H; Alberti KG Br Med J (Clin Res Ed); 1981 Jan; 282(6261):347-50. PubMed ID: 6780019 [TBL] [Abstract][Full Text] [Related]
11. Intensive insulin therapy: Part II. Multicomponent insulin regimens. Hirsch IB; Herter CD Am Fam Physician; 1992 Jun; 45(6):2643-8. PubMed ID: 1595513 [TBL] [Abstract][Full Text] [Related]
12. Improved control in diabetes with continuous subcutaneous insulin infusion. Schiffrin A; Colle E; Belmonte M Diabetes Care; 1980; 3(6):643-9. PubMed ID: 7004811 [TBL] [Abstract][Full Text] [Related]
13. A crossover comparison of continuous subcutaneous insulin infusion (CSII) against multiple insulin injections in insulin-dependent diabetic subjects: improved control with CSII. Home PD; Capaldo B; Burrin JM; Worth R; Alberti KG Diabetes Care; 1982; 5(5):466-71. PubMed ID: 6765222 [TBL] [Abstract][Full Text] [Related]
14. Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients. Laursen T; Jørgensen JO; Jakobsen G; Hansen BL; Christiansen JS J Clin Endocrinol Metab; 1995 Aug; 80(8):2410-8. PubMed ID: 7543114 [TBL] [Abstract][Full Text] [Related]
15. Control of insulin-dependent diabetes with portable miniaturized infusion systems. Hepp KD; Renner R; Piwernetz K; Mehnert H Diabetes Care; 1980; 3(2):309-13. PubMed ID: 6993145 [TBL] [Abstract][Full Text] [Related]
17. Continuous subcutaneous insulin infusion: improved blood-glucose and intermediary-metabolite control in diabetics. Pickup JC; Keen H; Parsons JA; Alberti KG; Rowe AS Lancet; 1979 Jun; 1(8129):1255-7. PubMed ID: 87724 [TBL] [Abstract][Full Text] [Related]
18. Reproducibility of insulin dosage on consecutive days of blood glucose control by an artificial beta-cell in brittle diabetic patients. Bruns W; Bombor H; Jutzi E; Ratzmann KP; Schulz B; Abel P; Fischer U Diabetes Care; 1983; 6(2):112-7. PubMed ID: 6343014 [TBL] [Abstract][Full Text] [Related]
19. Combined continuous subcutaneous insulin infusion and multiple subcutaneous injections in type I diabetic patients. Schiffrin A; Belmonte M Diabetes Care; 1981; 4(6):595-600. PubMed ID: 6751734 [TBL] [Abstract][Full Text] [Related]
20. Reversal of insulin resistance in type I diabetes after treatment with continuous subcutaneous insulin infusion. Lager I; Lönnroth P; von Schenck H; Smith U Br Med J (Clin Res Ed); 1983 Dec; 287(6406):1661-4. PubMed ID: 6416540 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]